{"id":929996,"date":"2026-01-22T17:32:55","date_gmt":"2026-01-22T22:32:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/"},"modified":"2026-01-22T17:32:55","modified_gmt":"2026-01-22T22:32:55","slug":"madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/","title":{"rendered":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CONSHOHOCKEN, Pa., Jan.  22, 2026  (GLOBE NEWSWIRE) &#8212; Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on January 15, 2026 to 40 new non-executive employees as equity inducement awards under the terms of Madrigal\u2019s 2025 Inducement Plan. The equity awards were approved by Madrigal\u2019s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p>The equity awards were granted as an inducement material to employees\u2019 acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 3,049 shares of Madrigal\u2019s common stock, and in the aggregate 13,145 time-based restricted stock units. Options have an exercise price of $495.88 per share, which is equal to the closing price of the company\u2019s common stock on the grant date. Options vest as follows: (i) 25% of the option shares will vest on the first anniversary of the grant date and (ii) 6.25% of the option shares will vest on each quarterly anniversary following the first anniversary of the grant date. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee\u2019s continued employment as of the applicable vesting date.<\/p>\n<p>\n        <strong>About Madrigal Pharmaceuticals<\/strong>\n      <\/p>\n<p>Madrigal Pharmaceuticals, Inc.\u00a0(Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal\u2019s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-\u03b2 agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and\u00a0European Commission\u00a0for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wl-a96pk7abj3-iR09CFiUO2r0aZCr24KXnCNI3d9-coU6s1V6bkOqz2hypeow0sF-n-5da-Yo0G8zwy8yiECmIuMJkF3CQpMf8379k_X3zk-p5qUyUzEfpf5WMwM_ZHxdCgmlwLnFIoBI338zFvwY-n18vQ-1OPN3XxqHdcUteV71WYVMZGTfLMU_8iRTo4H7S442fFvNFYFc6x_nAGQeNA_mQdvZeouR5u0fFz6qgHOS4gYQ5jVtJ0knLF_D9rQIQ0N3YPhSPIk7Ey8mn0_w==\" rel=\"nofollow\" target=\"_blank\">www.madrigalpharma.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact <\/strong><br \/>\n        <br \/>Tina Ventura, IR@madrigalpharma.com<\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Christopher Frates, media@madrigalpharma.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYzMDg4MyM3Mzc2MTQ4IzIwMDYyMTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2NiODk4NTctNWEwYi00NmI1LWFkMDctMzA3NTNlNjgyMDRjLTEwMTc3ODYtMjAyNi0wMS0yMi1lbg==\/tiny\/Madrigal-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CONSHOHOCKEN, Pa., Jan. 22, 2026 (GLOBE NEWSWIRE) &#8212; Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on January 15, 2026 to 40 new non-executive employees as equity inducement awards under the terms of Madrigal\u2019s 2025 Inducement Plan. The equity awards were approved by Madrigal\u2019s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees\u2019 acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 3,049 shares of Madrigal\u2019s common stock, and in the aggregate 13,145 time-based restricted stock units. Options have an exercise price of $495.88 per &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-929996","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CONSHOHOCKEN, Pa., Jan. 22, 2026 (GLOBE NEWSWIRE) &#8212; Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on January 15, 2026 to 40 new non-executive employees as equity inducement awards under the terms of Madrigal\u2019s 2025 Inducement Plan. The equity awards were approved by Madrigal\u2019s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees\u2019 acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 3,049 shares of Madrigal\u2019s common stock, and in the aggregate 13,145 time-based restricted stock units. Options have an exercise price of $495.88 per &hellip; Continue reading &quot;Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T22:32:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYzMDg4MyM3Mzc2MTQ4IzIwMDYyMTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-01-22T22:32:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\\\/\"},\"wordCount\":345,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYzMDg4MyM3Mzc2MTQ4IzIwMDYyMTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\\\/\",\"name\":\"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYzMDg4MyM3Mzc2MTQ4IzIwMDYyMTM=\",\"datePublished\":\"2026-01-22T22:32:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYzMDg4MyM3Mzc2MTQ4IzIwMDYyMTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYzMDg4MyM3Mzc2MTQ4IzIwMDYyMTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/","og_locale":"en_US","og_type":"article","og_title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"CONSHOHOCKEN, Pa., Jan. 22, 2026 (GLOBE NEWSWIRE) &#8212; Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on January 15, 2026 to 40 new non-executive employees as equity inducement awards under the terms of Madrigal\u2019s 2025 Inducement Plan. The equity awards were approved by Madrigal\u2019s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees\u2019 acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 3,049 shares of Madrigal\u2019s common stock, and in the aggregate 13,145 time-based restricted stock units. Options have an exercise price of $495.88 per &hellip; Continue reading \"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-22T22:32:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYzMDg4MyM3Mzc2MTQ4IzIwMDYyMTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-01-22T22:32:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/"},"wordCount":345,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYzMDg4MyM3Mzc2MTQ4IzIwMDYyMTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/","name":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYzMDg4MyM3Mzc2MTQ4IzIwMDYyMTM=","datePublished":"2026-01-22T22:32:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYzMDg4MyM3Mzc2MTQ4IzIwMDYyMTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYzMDg4MyM3Mzc2MTQ4IzIwMDYyMTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-11\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/929996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=929996"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/929996\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=929996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=929996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=929996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}